Literature DB >> 6182777

Effect of immunomodulating agents on leucocyte chemotaxis and cyclic nucleotides.

M Roch-Arveiller, M Tissot, L Moachon, J P Giroud.   

Abstract

We have studied the effect of immunomodulating agents on polymorphonuclear leucocyte chemotaxis and their relation to the modification of cyclic nucleotide levels. The tested drugs (levamisole, tuftsin, azimexon, muramyl dipeptide, isoprinosine) inhibited the chemotaxis of 'normal' cells but restored the impaired chemotactic responsiveness of inflammatory cells. None of these drugs had any significant effect on cyclic nucleotide levels in 'normal' cells. All the drugs, except isoprinosine, produced an increase in the cGMP levels in inflammatory cells. These results suggest that immunomodulators are able to modify PMN chemotaxis. This effect cannot, however, be related to modification of the cyclic nucleotide levels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182777     DOI: 10.1007/bf01965403

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  28 in total

1.  Plasma and cell-derived inhibitors of human neutrophil chemotaxis.

Authors:  E J Goetzl
Journal:  Ann N Y Acad Sci       Date:  1975-06-13       Impact factor: 5.691

2.  A simple ultrasensitive method for the assay of cyclic AMP and cyclic GMP in tissues.

Authors:  E K Frandsen; G Krishna
Journal:  Life Sci       Date:  1976-03-01       Impact factor: 5.037

3.  Guanosine 3', 5'-cyclicmonophosphate assay at 10(-15)-mole level.

Authors:  H L Cailla; C J Vannier; M A Delaage
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

4.  The comparative effects of isoprinosine, levamisole, muramyl dipeptide and SM1213 on lymphocyte and macrophage proliferation and activation in vitro.

Authors:  J W Hadden; A Englard; J R Sadlik; E M Hadden
Journal:  Int J Immunopharmacol       Date:  1979

Review 5.  Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents.

Authors:  L Chedid; F Audibert; A G Johnson
Journal:  Prog Allergy       Date:  1978

6.  Adenosine 3',5' cyclic monophosphate assay at 10-15 mole level.

Authors:  H L Cailla; M S Racine-Weisbuch; M A Delaage
Journal:  Anal Biochem       Date:  1973-12       Impact factor: 3.365

7.  Migration enhancement by tuftsin of human mononuclear cells and its effect on the migration inhibition factor test with tumor antigens.

Authors:  K Nishioka
Journal:  Gan       Date:  1978-08

Review 8.  Levamisole and inosiplex: antiviral agents with immunopotentiating action.

Authors:  J W Hadden; C Lopez; R J O'Reilly; E M Hadden
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

9.  Non-specific MIF-like activity induced by the synthetic immunoadjuvant: N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP).

Authors:  A Adam; V Souvannavong; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1978-11-29       Impact factor: 3.575

10.  Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.

Authors:  M Parant; F Parant; L Chedid; A Yapo; J F Petit; E Lederer
Journal:  Int J Immunopharmacol       Date:  1979
View more
  4 in total

Review 1.  Mechanism of GM-CSF stimulation of neutrophils.

Authors:  R G Coffey
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Acute pancreatitis, bacterial translocation, and different octreotide regimens: an experimental study.

Authors:  Osman Güler; Saadet Akturan; Erol Kisli; Iştar Dolapçi; Muzaffer Caydere; Atilla Akova
Journal:  Surg Today       Date:  2009-09-27       Impact factor: 2.549

3.  Uveitis induction in the rabbit by muramyl dipeptides.

Authors:  R V Waters; T G Terrell; G H Jones
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

Review 4.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.